Source: Arch Therapeutics, Inc.
Terrence Norchi, MD, CEO of Arch Therapeutics, Inc. (OTCQB: ARTH)
("Arch" or the "Company"), developer of novel liquid, gel and solid
hemostatic and wound care devices, will present a corporate update at
the 29th Annual Roth Conference, which will take place from March 12-15,
2017 at The Ritz-Carlton, Laguna Niguel in Dana Point, California.
The presentation is scheduled for Monday, March 13, 2017 at
12:30 PM PT (3:30 PM ET). Dr. Norchi will be available to meet with
investors who are registered to attend the conference. If you are an
investor and wish to attend the Company's presentation or schedule a
meeting, please click the following link: http://www.roth.com/main/page.aspx?PageID=7280.
You may access the live webcast by visiting: http://wsw.com/webcast/roth31/arth. The presentation will be available for download at: http://ir.archtherapeutics.com.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a medical device company
developing a novel approach to stop bleeding (hemostasis) and control
leaking (sealant) during surgery and trauma care. Arch is developing
products based on an innovative self-assembling materials technology
platform with the goal of making surgery and interventional care faster
and safer for patients. Arch's flagship development stage product
candidates, known as the AC5 Surgical Hemostatic Device™ and AC5 Topical
Hemostatic Device™, are being designed to achieve hemostasis during
surgical, wound and interventional care.
About Roth Capital Partners, LLC
Roth Capital Partners, LLC (ROTH) is a
relationship-driven investment bank focused on serving emerging growth
companies and their investors. As a full-service investment bank, ROTH
provides capital raising, M&A advisory, analytical research,
trading, market-making services and corporate access. Headquartered in
Newport Beach, CA, ROTH is privately-held and employee owned, and
maintains offices throughout the U.S. For more information on ROTH,
please visit www.roth.com.
No comments:
Post a Comment